Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13538-13545
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13538
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13538
HS risk classes | Mean recurrence-free survivaltime (± SE; years) | 5-yr recurrence-free survivalrate (± SE) | Hazard ratio(95%CI)1 | HCC recurrence cases | HCC-related deaths |
Low (HS: 0-1; n = 61) | 6.60 ± 0.15 | 96.7% ± 2.3% | 1.00 | 2 (3.3) | 1 (1.6) |
Moderate (HS: 1-2; n = 27) | 5.43 ± 0.45 | 77.9% ± 8.9% | 6.37 (1.23-32.86) | 5 (18.5) | 3 (11.1) |
High (HS: >2; n = 13) | 2.92 ± 0.21 | 40.0% ± 14.6% | 23.18 (4.80-111.96) | 7 (53.8) | 5 (38.5) |
- Citation: Vasuri F, Malvi D, Rosini F, Baldin P, Fiorentino M, Paccapelo A, Ercolani G, Pinna AD, Golfieri R, Morselli-Labate AM, Grigioni WF, D’Errico-Grigioni A. Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. World J Gastroenterol 2014; 20(37): 13538-13545
- URL: https://www.wjgnet.com/1007-9327/full/v20/i37/13538.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i37.13538